Chronic Myeloid Leukemia

Jorge Cortes, Michael Deininger (Herausgeber)

Buch | Hardcover

172 Seiten

2006
Crc Press Inc (Verlag)
978-0-8493-7955-0 (ISBN)

Titel z.Zt. nicht lieferbar
Versandkostenfrei
Auch auf Rechnung

Artikel merken

Chronic Myeloid Leukemia (CML) remains a key model for the improved understanding of the pathophysiology of a malignancy at a molecular level and has been used by researchers to develop a variety of therapies and therapeutic assessment methods. This concise, readable guide assembles and synthesizes the latest developments and trends in the treatment of CML and provides an authoritative and convenient summary of the latest progress in imatinib trials, the molecular monitoring of CML responses, and the engineering of new therapies to overcome resistance and improve patient care.

Providing critical insight and exploration of models that will enhance the cancer community at large, this source:

stands as the only source to focus on post-Gleevec developments in CML therapeutics

collects information from the forefront of the field—helping busy clinicians make informed management decisions

supplies critical research from recognized opinion leaders on the topic

provides an overview of the current status of new transplant modalities

contains a vivid selection of color photographs

JORGE CORTES is Deputy Chair, Department of Leukemia, and Professor of Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas. A member of several medical societies, Dr. Cortes has served as a lecturer and the author/co-author of over 300 medical publications and abstracts and has greatly contributed to the search for effective treatments for leukemias. Dr. Cortes is the recipient of a variety of awards including the Merit Award (1995) from American Society of Clinical Oncology, the Upjohn Outstanding Research Award (1995) from M.D. Anderson Cancer Center, and was recently a Clinical Research Scholar for the Leukemia Lymphoma Society. Dr. Cortes is the recipient of the Faculty Scholar Award from M.D. Anderson (2003), and the Celgene Young Investigator Award (2005). MICHAEL DEININGER is Scientific Director of the CML Basic Research Program and Assistant Professor, Center for Hematologic Malignancies, Oregon Health & Science University, Portland. Dr. Deininger is a member of the American Society of Hematology and the American Society of Clinical Oncology. He received the M.D. degree from the University of Wuerzburg, Germany, and the Ph.D. degree from Imperial College, London. He has published numerous research and scholarly articles in peer-reviewed journals, covering molecular and clinical aspects of CML, and serves as a peer reviewer for Blood, Nature Genetics, The Lancet, Cancer Research, and other professional journals. Dr. Deininger’s honors include scholarships from the German Scholarship Foundation and the American Society of Hematology.

BCR-ABL as a Molecular Target. Long-Term Results of Stem Cell Transplant. Where are We Today with Imatinib Therapy. Monitoring CML in 2006. Monitoring CML in 2006. Dasatinib: a Dual Abl and Src Inhibitor. AMN107. Resistance to Imatinib. Immunotherapy. Non-Immunological, non TKI Targets. Non-Immunological, non TKI Targets. CML in Transformation. Early Intensification of Therapy

Erscheint lt. Verlag	13.12.2006
Verlagsort	Bosa Roca
Sprache	englisch
Maße	152 x 229 mm
Gewicht	408 g
Themenwelt	Schulbuch / Wörterbuch ► Lexikon / Chroniken
	Medizin / Pharmazie ► Allgemeines / Lexika
	Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie
	Medizin / Pharmazie ► Medizinische Fachgebiete ► Pädiatrie
ISBN-10	0-8493-7955-5 / 0849379555
ISBN-13	978-0-8493-7955-0 / 9780849379550
Zustand	Neuware